Vor Biopharma Inc. (VOR) stock
VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$17.83−0.35 (-1.93%)
Close on Nov 18, 2026Market cap $1.10BP/E –Yield –
Vor Biopharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Vor Biopharma's free cash flow for the twelve months ending Sep 30, 2026 was -$119.68M. For fiscal 2025 it was -$143.65M. The highest annual figure on record is -$40.45M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$143.65M | – |
| FY2024 | Dec 31, 2024 | -$99.89M | – |
| FY2023 | Dec 31, 2023 | -$101.36M | – |
| FY2022 | Dec 31, 2022 | -$93.61M | – |
| FY2021 | Dec 31, 2021 | -$73.04M | – |
| FY2020 | Dec 31, 2020 | -$40.45M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$32.77M | – |
| Q2 FY2026 | Jun 30, 2026 | -$25.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$38.29M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$53.91M | – |
| Q2 FY2025 | Jun 30, 2025 | -$35.34M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.30M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.14M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.32M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.86M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.58M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$28.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$24.50M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.36M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$19.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.92M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.76M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.98M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.48M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.82M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.11M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.83M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.88M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.63M | – |
See a number that looks wrong?